A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis

16235CLOU064C12306OpenA randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosisIndustrialAdultTreatmentOtherAmjad, Faria; Barry, BrianMedStar Health and GUMC; Medstar Montgomery Medical Center; Medstar Washington Hospital Center : Anu BhooshanMedStar Neuroscience & Rehab Research Network16668Anu BhooshanAnu Bhooshananu.r.bhooshan@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>